Oxbryta is specifically designed to intervene in the
sickle cell disease (SCD) cascade1

The unique mechanism of action (MOA) of Oxbryta directly inhibits the root cause of sickling in SCD1,2

Icon of Oxbryta® binding directly to your patient's hemoglobin S (HbS) molecules

Bind

Oxbryta binds directly to your patient’s hemoglobin S (HbS) molecules

Icon depicting Oxbryta® dose-dependent binding increases oxygen affinity, inhibiting polymerization of the HbS molecule

Inhibit

This dose-dependent binding increases oxygen (O2) affinity, inhibiting polymerization of the HbS molecule

Icon depicting healthy and sickled red blood cells

Reduce

Nonclinical studies suggest that Oxbryta may inhibit red blood cell (RBC) sickling, improve RBC deformability, and reduce whole blood viscosity

Icon depicting improved anemia and reduced hemolysis

Improve

Improve anemia (as measured by an increase in hemoglobin) and reduce hemolysis (as measured by indirect bilirubin and percent reticulocyte count)

  • Hemoglobin S (HbS) molecules have a lower affinity for O2
  • When HbS releases oxygen, it can polymerize into long, rigid rods, deforming the red blood cells (RBCs) into their sickled shape
  • These long, rigid rods deform the RBCs into sickled RBCs

Get the latest information about Oxbryta delivered to your inbox